利福霉素抗性突变菌Streptomyces sp.HS-NF-1046R中的两个新化合物

Two new compounds from rifamycin resistant mutant strain Streptomyces sp. HS-NF-1046R

采用硅胶色谱、凝胶色谱及液相色谱分离纯化一株利福霉素抗性突变菌Streptomyces sp. HS-NF-1046R发酵物中的次级代谢产物,通过波谱技术鉴定了3个化合物:3-hydroxyl-2-N-propionyl-anthranilamide (1)、2,3-dihydro-8-hydroxy-2,2-dimethyl quinazolin-4-(1H)-one (2)和2-aminobenzamide (3),其中1和2是新化合物。通过SRB法评价新化合物的细胞毒活性,化合物1和2对人肺癌细胞A549、人肝癌细胞HepG2、人结肠癌细胞HCT-116和白血病细胞K562的IC_(50)值均大于100μmol·L^(-1),未表现出明显的细胞毒性。

Using silica gel column chromatography, gel chromatography and HPLC, we isolated secondary metabolites in fermentation broth of a rifamycin resistant mutation strain Streptomyces sp. HS-NF-1046 R. Based on spectroscopic data, the chemical structures of three compounds were identified as 3-hydroxyl-2-N-propionyl-anthranilamide(1), 2, 3-dihydro-8-hydroxy-2, 2-dimethyl quinazolin-4-(1 H)-one(2) and 2-aminobenzamide(3).Compounds 1 and 2, as new entities, were evaluated for cytotoxicity against A549, HepG2, HCT-116 and K562 cells using the SRB assay. Compounds 1 and 2 exhibited no cytotoxicity with IC50 over 100 μmol·L-1.